Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

HIV Infections Clinical Trial

Official title:

A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00632970
• Other study ID #: GS001
• Status: Terminated
• Phase: Phase 4
• Start date: February 2008
• Est. completion date: June 2010

Study information

• Verified date: August 2018
• Source: George Washington University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy. All patients will receive concomitant therapy with Truvada.

Description:

It is hypothesized that (1) the raltegravir regimen will have similar efficacy in terms of both viral suppression as well as increases in CD4 cell counts and (2) raltegravir will have significantly less impact on plasma lipids, lipoproteins and lipoproteins subtypes, compared with lopinavir/ritonavir.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: June 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Documented HIV infection confirmed by western blot or HIV RNA.

2. At least 18 years of age.

3. Less than 1 week of prior antiretroviral therapy.

4. In the opinion of the investigator, patients should be clinically stable. Patients may be on chronic suppressive therapy for opportunistic infections such as MAC or CMV.

5. Patients who are of reproductive potential agree to use an acceptable method of birth control throughout the study. Acceptable methods include an intrauterine device (IUD), diaphragm with spermicide, condoms, or abstinence.

6. HIV RNA > 5000 copies/ml. No restriction on CD4 cell count.

7. A negative urine pregnancy test on the day of initiation of therapy.

Exclusion Criteria:

1. Prior treatment with >1week of antiretroviral therapy.

2. Patient requires or is anticipated to require any of the prohibited medications noted in the protocol.

3. HIV RNA < 5000 prior to receiving therapy.

4. Baseline resistance to any of the study regimen drugs on genotype testing.

5. Patients with acute hepatitis due to any cause or clinically significant chronic liver disease.

6. Patient with severe renal insufficiency defined as a calculated creatinine clearance at time of screening <30mL/min, based on the Cockcroft-Gault equation which is as follows (and 0.85X this value for females): Clcr(mL/min) = (l40-age) x weight (in kg)72 x serum creatinine (mg/dL).

7. Patient has a condition (including but not limited to alcohol or other substance abuse) which in the opinion of the investigator would interfere with patient compliance or safety.

8. A female patient who is pregnant, breast-feeding, or expecting to conceive or donate eggs during the study; or a male patient who is planning to impregnate or provide sperm donation during the study is excluded.

9. Inability to obtain signed informed consent from a patient age 18 or older.

10. Patient has significant hypersensitivity or other contraindication to any of the components of the study drug.

11. Patients who should be treated for hyperlipidemia as per NCEPIII guidelines and patients who are currently receiving lipid-lowering therapy are excluded.

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Raltegravir
1, 400mg tablet twice a day, with Truvada 1 tablet once a day
• Lopinavir/Ritonavir
2 tablets twice a day, with Truvada 1 tablet once a day
• Truvada
1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)

Locations

Country	Name	City	State
United States	George Washington University Medical Faculty Associates	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
George Washington University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute Change in CD4 Cell Counts		24 and 48 weeks
Secondary	Change is Plasma Lipids, Lipoproteins and Lipoprotein Subtypes.		24 weeks